CN1709400A - Medicine for treating ulcer haemorrhage - Google Patents
Medicine for treating ulcer haemorrhage Download PDFInfo
- Publication number
- CN1709400A CN1709400A CN 200510049985 CN200510049985A CN1709400A CN 1709400 A CN1709400 A CN 1709400A CN 200510049985 CN200510049985 CN 200510049985 CN 200510049985 A CN200510049985 A CN 200510049985A CN 1709400 A CN1709400 A CN 1709400A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- portions
- flavor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine for curing haemorrhagia due to ulcerative disease with obvious therapeutic effect. Said medicine is made up by using 8 Chinese medicinal materials of (by weight portion) 15-25 portions of astragalus root, 10-20 portions of codonopsis root, 8-16 portions of ovate atractylodes root, 10-20 portions of dried/fresh rehmannia, 8-16 portions of bletilla tuber, 8-16 portions of rhubarb, 10-20 portions of salvia root and 2-6 portions of licorice.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of ulcer haemorrhage, belong to the medicine of treatment ulcer haemorrhage disease
Technical field.
Background technology:
It is hemorrhage that ulcer haemorrhage is meant that stomach, duodenal bulbar ulcer cause.Clinical manifestation is hematemesis or separates pitch sample stool.Ulcer haemorrhage is a kind of common disease, though it is more to treat at present the medicine of this disease, mostly is Western medicine greatly, though these Western medicine have certain curative effect, it exists the phenomenon of toxic and side effects also relatively more serious; It is higher that existing in addition Western medicine ubiquity medical expense, and treatment time is longer, and the also less-than-ideal problem of curative effect, and therefore, the result of use of the medicine of existing treatment ulcer haemorrhage disease still is not ideal.
Summary of the invention:
The objective of the invention is: provide a kind of therapeutic effect better, have no side effect, the medicine of treatment ulcer haemorrhage disease that medical expense is lower, to overcome the deficiencies in the prior art.
The present invention is achieved in that this medicine by the Radix Astragali, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the Radix Rehmanniae, the medicament made of loft, Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae and Radix Glycyrrhizae eight flavor Chinese medicines in vain, and each Chinese medicine proportioning by weight of distinguishing the flavor of is: 15～25 parts of the Radixs Astragali, 10～20 parts of Radix Codonopsis, 8～16 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts in the Radix Rehmanniae, white loft 8～16 parts, 8～16 parts of Radix Et Rhizoma Rhei, 10～20 parts of Radix Salviae Miltiorrhizaes, 2～6 parts in Radix Glycyrrhizae.
The ratio range of formula optimization weight portion of preparation medicine of the present invention is: 16～20 parts of the Radixs Astragali, 13～17 parts of Radix Codonopsis, 10～14 parts of the Rhizoma Atractylodis Macrocephalaes, 13～17 parts in the Radix Rehmanniae, white loft 10～14 parts, 10～14 parts of Radix Et Rhizoma Rhei, 13～17 parts of Radix Salviae Miltiorrhizaes, 3～5 parts in Radix Glycyrrhizae.
The proportioning of optimum weight part of medicine of the present invention is: 18 parts of the Radixs Astragali, 15 parts of Radix Codonopsis, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts in the Radix Rehmanniae, white loft 12 parts, 12 parts of Radix Et Rhizoma Rhei, 15 parts of Radix Salviae Miltiorrhizaes, 4 parts in Radix Glycyrrhizae.
The said medicament of the present invention is a said dosage form on any pharmaceutics.
Best medicament of the present invention is an oral liquid formulation.
In prescription of the present invention: the Radix Astragali: sweet in the mouth, tepor, nontoxic have benefit and defend effects such as consolidating superficial resistance, promoting pus discharge and tissue regeneration strengthening, inducing diuresis to remove edema; Radix Codonopsis: nature and flavor are sweet, flat, have the effect that invigorating the spleen and replenishing QI, spleen invigorating are promoted the production of body fluid; The Rhizoma Atractylodis Macrocephalae: warm in nature, bitter in the mouth, sweet has invigorating the spleen and benefiting QI, dampness diuretic, antisudorific effect; The Radix Rehmanniae: sweet in the mouth, hardship, cold in nature, GUIXIN, liver, lung meridian have the effect of clearing away heat and cooling blood; Loft in vain: nature and flavor hardship, puckery, cold, matter is sticking and puckery, goes into lung, stomach, Liver Channel, has the effect of astringing to arrest bleeding, detumescence and promoting granulation; Radix Et Rhizoma Rhei: the nature and flavor bitter cold, return spleen, stomach, large intestine, liver, the pericardium Five Classics, have the function of purging heat to relax the bowels, removing mass clots absorbing, clearing away damp-heat; Radix Salviae Miltiorrhizae: cold nature, bitter in the mouth, GUIXIN, Liver Channel have stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, an effect of the relieving restlessness that clears away heart-fire; Radix Glycyrrhizae is the Chinese medicine of using always, can lower or alleviate bias, the toxicity of other drug, and tool is auxiliary, coordination, flavored action, and Radix Glycyrrhizae property is flat, sweet in the mouth, has the function of spleen reinforcing, lung moistening, detoxifcation, coordinating the actions of various ingredients in a prescription.
The present invention is according to traditional experience, and in conjunction with the pathomechanism of modern medicine, thinks that ulcer haemorrhage is mainly caused by insufficiency of the spleen, stagnation of liver-QI or gastric heat, should treat with the medicine of promoting the circulation of blood blood stasis dispelling.Therefore the present invention is directed to the characteristics of ulcer haemorrhage disease, through long-term experiment, comparison and research, after above-mentioned inexpensive and Chinese medicine that have no side effect commonly used carried out rational formula, make the Chinese medicine of respectively distinguishing the flavor of to coordinate to bring into play jointly its property of medicine mutually based on the promoting the circulation of blood blood stasis dispelling.Through clinical verification, the present invention has the effect of heat clearing away preferably, hemostasis and promoting the circulation of blood blood stasis dispelling, when being used for the treatment of ulcer haemorrhage, compare with existing medicine, the present invention also have therapeutic effect better, have no side effect, advantage that medical expense is low.
The specific embodiment:
Embodiments of the invention: get the Radix Astragali 18 grams, Radix Codonopsis 15 grams, the Rhizoma Atractylodis Macrocephalae 12 grams, the Radix Rehmanniae 15 grams, white loft 12 grams, Radix Et Rhizoma Rhei 12 grams, Radix Salviae Miltiorrhizae 15 grams, Radix Glycyrrhizae 4 grams, as pharmaceutical raw material, each raw material is cleaned the back to be soaked 20～30 minutes earlier with 1000 milliliters～1200 ml waters, decocted again 20～50 minutes after then it being boiled, after the cooling, medicinal residues are filtered out, get its medicinal liquid and can make oral liquid formulations of the present invention.Oral liquid formulations of the present invention also routinely the oral liquid processing technology be made; And other dosage form (as dosage forms such as tablet, pill, capsules) can be made by the method for corresponding conventional dosage form.
The instructions about how to take medicine of oral liquid formulations of the present invention are: sooner or later respectively obey 1 time every day 2 times, each 50～60 milliliters, general 6～10 days is a course of treatment.
Be the clinical observation that employing the present invention treats uremic patient below, so that curative effect of the present invention is further described:
1 patient's epigastrium dull pain January of case, surplus and companion's melena was 3 days, and every day one is to secondary, each about 50 to 100 milliliters.Stool blood experiment (+++), the conscious dizziness of patient, cardiopalmus, appetite is not good enough.Test its hemoglobin 9 gram %, erythrocyte 3,200,000/cubic millimeter through sanguification.
The patient took the present invention after 2 days, and stool changes isabelline and is shaped, and dizzy, cardiopalmus alleviates; Stool blood experiment (+).The patient continues to take the present invention after 4 days again, and its dizziness, cardiopalmus disappear, and appetite is clearly better, stool blood experiment ().After this drug withdrawal continues to observe ten days, and stool test twice is not seen hemorrhage.Do not see recurrence afterwards yet.
Case 2 patients bimester stomachache before clothes the present invention, and after vomitting a small amount of coffee-like thing, that continues pitch sample stool occurs, is " duodenal bulbar ulcer " through hospital diagnosis.The present invention a few days ago arranges pitch sample melena again at clothes, measure mediumly every day 2 to 3 times, and epigastrium dull pain connects and coerces rib.Through chemical examination, the real test of its stool blood (+++).
The patient took the present invention after 6 days, and gastric abscess alleviates, and it is yellow that stool changes, Fecal Occult Blood Testing ().Continue to take the present invention two days later, gastric abscess ends entirely again, and surplus disease is also removed, and it is yellow that stool changes, and twice of Fecal Occult Blood Testing is all negative.Do not see recurrence afterwards yet.
Taking during the present invention treats, any untoward reaction does not all appear in the patient.
Claims (5)
1, a kind of medicine for the treatment of ulcer haemorrhage, it is characterized in that: this medicine is by the Radix Astragali, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, the Radix Rehmanniae, the medicament made of loft, Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae and Radix Glycyrrhizae eight flavor Chinese medicines in vain, and each Chinese medicine proportioning by weight of distinguishing the flavor of is: 15～25 parts of the Radixs Astragali, 10～20 parts of Radix Codonopsis, 8～16 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts in the Radix Rehmanniae, white loft 8～16 parts, 8～16 parts of Radix Et Rhizoma Rhei, 10～20 parts of Radix Salviae Miltiorrhizaes, 2～6 parts in Radix Glycyrrhizae.
2, the medicine of treatment ulcer haemorrhage according to claim 1 is characterized in that: each Chinese medicine proportioning by weight of distinguishing the flavor of is: 16～20 parts of the Radixs Astragali, 13～17 parts of Radix Codonopsis, 10～14 parts of the Rhizoma Atractylodis Macrocephalaes, 13～17 parts in the Radix Rehmanniae, white loft 10～14 parts, 10～14 parts of Radix Et Rhizoma Rhei, 13～17 parts of Radix Salviae Miltiorrhizaes, 3～5 parts in Radix Glycyrrhizae.
3, the uremic medicine of treatment according to claim 1 is characterized in that: each Chinese medicine best proportioning by weight of distinguishing the flavor of is: 18 parts of the Radixs Astragali, 15 parts of Radix Codonopsis, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts in the Radix Rehmanniae, white loft 12 parts, 12 parts of Radix Et Rhizoma Rhei, 15 parts of Radix Salviae Miltiorrhizaes, 4 parts in Radix Glycyrrhizae.
4, the medicine of treatment ulcer haemorrhage according to claim 1 is characterized in that: said medicament is a said dosage form on any pharmaceutics.
5, the medicine of treatment ulcer haemorrhage according to claim 4 is characterized in that: said medicament is an oral liquid formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100499858A CN1320899C (en) | 2005-06-07 | 2005-06-07 | Medicine for treating ulcer haemorrhage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100499858A CN1320899C (en) | 2005-06-07 | 2005-06-07 | Medicine for treating ulcer haemorrhage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1709400A true CN1709400A (en) | 2005-12-21 |
| CN1320899C CN1320899C (en) | 2007-06-13 |
Family
ID=35705732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100499858A Expired - Fee Related CN1320899C (en) | 2005-06-07 | 2005-06-07 | Medicine for treating ulcer haemorrhage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1320899C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850044A (en) * | 2010-06-07 | 2010-10-06 | 王建武 | Medicament for treating peptic ulcer and reflux esophagitis and preparation method thereof |
| CN102670831A (en) * | 2012-05-28 | 2012-09-19 | 石家庄平安医院有限公司 | Medicinal composition for treating dermatomyositis and preparation method thereof |
| CN103599367A (en) * | 2013-11-15 | 2014-02-26 | 刘桂沅 | Capsule for gastrointestinal ulcer and preparation technology thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1208646A (en) * | 1998-09-08 | 1999-02-24 | 郭旸 | Medicine for treating gastrointestinal ulcer and gastritis |
-
2005
- 2005-06-07 CN CNB2005100499858A patent/CN1320899C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850044A (en) * | 2010-06-07 | 2010-10-06 | 王建武 | Medicament for treating peptic ulcer and reflux esophagitis and preparation method thereof |
| CN101850044B (en) * | 2010-06-07 | 2011-11-02 | 王建武 | Medicament for treating peptic ulcer and reflux esophagitis and preparation method thereof |
| CN102670831A (en) * | 2012-05-28 | 2012-09-19 | 石家庄平安医院有限公司 | Medicinal composition for treating dermatomyositis and preparation method thereof |
| CN102670831B (en) * | 2012-05-28 | 2014-04-02 | 石家庄平安医院有限公司 | Medicinal composition for treating dermatomyositis and preparation method thereof |
| CN103599367A (en) * | 2013-11-15 | 2014-02-26 | 刘桂沅 | Capsule for gastrointestinal ulcer and preparation technology thereof |
| CN103599367B (en) * | 2013-11-15 | 2016-02-17 | 刘桂沅 | Capsule for gastrointestinal ulcer and preparation technology thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1320899C (en) | 2007-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101347612B (en) | Compound medicament for treating common cold cough and acute/chronic bronchitis, and preparation method thereof | |
| CN105535471A (en) | Pill medicine for treating panasthenia and preparation method thereof | |
| CN103550687B (en) | A kind of Chinese medicine composition for the treatment of the hepatic and renal YIN deficiency | |
| CN102462827A (en) | Traditional Chinese medicinal powder formulation for treating postpartum mastitis of Boer goat | |
| CN104758487A (en) | Traditional Chinese medicine composition for treating exfoliative cheilitis | |
| CN104940810A (en) | Traditional Chinese medicine composition for treating angina | |
| CN101703742B (en) | Preparation method of granules for treating acne caused by qi deficiency causing blood stasis and phlegm-heat stagnation | |
| CN103211990B (en) | Chinese medicinal composition for treating oral ulcer | |
| CN1320899C (en) | Medicine for treating ulcer haemorrhage | |
| CN104225166A (en) | Chinese medicine composition for treating amenorrhea and preparation method thereof | |
| CN103330868A (en) | Intestinal tract replenishing liquid for chronic renal failure | |
| CN101966305A (en) | Traditional Chinese medicine for treating dental ulcer | |
| CN105902872A (en) | Traditional Chinese medicine composition for treating edema | |
| CN102166311B (en) | Preparation method of Chinese medicine for treating spleen-deficiency sthenic liver-energy hyperthyroidism | |
| CN105213831A (en) | A kind of Chinese medicine composition for the treatment of epidemic hemorrhagic fever | |
| CN101112443A (en) | Grass red capsule for treating gynaecologic leucorrhoea disease and method for preparing the same | |
| CN101085212A (en) | Traditional Chinese medicine for treating chronic nephritis | |
| CN1709408A (en) | Medicine for treating anaphylactoid purpura | |
| CN104042839A (en) | Traditional Chinese medicine composition for treating tinea versicolor | |
| CN103877374B (en) | A kind of for Chinese medicine treating diabetes and preparation method thereof | |
| CN103071125B (en) | Traditional Chinese medicament composition for treating endometriosis and preparation method thereof | |
| CN102319348B (en) | Medicament for treating chronic pharyngitis | |
| CN105456447A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition with function of promoting blood circulation to remove stasis and preparation method thereof | |
| CN105796816A (en) | Traditional Chinese medicine for treating kidney-deficiency stagnated-fire type oral ulcer | |
| CN104435704A (en) | Traditional Chinese medicine tablets for treating takayasu arteritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070613 |